<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39469091</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle><i>Mycoplasma pneumoniae</i> incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort study.</ArticleTitle><Pagination><StartPage>101103</StartPage><MedlinePgn>101103</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101103</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2024.101103</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED"><i>Mycoplasma pneumoniae</i> infections resurged globally in 2023-2024 after a three-year decline during the COVID-19 pandemic. We explored the incidence and severity of <i>M pneumoniae</i> infections in children and adolescents before, during, and after the pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This nationwide, population-based cohort study included all Danish children and adolescents aged 0-17 years with a positive <i>M pneumoniae</i> PCR test from May 1, 2016, to April 30, 2024. We obtained clinical details for patients hospitalised for 24 h or more. Risk ratios for infections, hospitalisations, and disease manifestations in 2023-2024 versus pre-COVID-19 seasons were calculated using Fisher's exact and Pearson's χ<sup>2</sup> tests. A season was defined from May 1 to April 30.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Among the Danish population of 1,152,000 children and adolescents, 14,241 with a positive PCR test for <i>M pneumoniae</i> were included. In 2023-2024, children and adolescents with a positive PCR rose 2.9-fold (95% CI 2.8-3.1; p &lt; 0.0001) compared to the pre-COVID-19 seasons, and hospitalisations rose 2.6-fold (95% CI 2.0-3.3; p &lt; 0.0001). <i>M pneumoniae</i>-induced rash and mucositis increased 5.3-fold (95% CI 1.8-15.3; p = 0.0007). In 2023-2024 compared to the pre-COVID-19 seasons, there was no difference in the proportion of hospitalisation (360 [4%] of 8165 versus 230 [4%] of 6009; p = 0.09), the median duration of hospital stay (3 days [IQR 2-5] versus 3 days [IQR 2-5]; p = 0.84), or paediatric intensive care unit admission (14 [4%] of 360 versus 9 [4%] of 230 p = 1.00).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">In Denmark, <i>M pneumoniae</i> infections and hospitalisations increased three-fold in 2023-2024 compared with the pre-COVID-19 seasons, indicating an immunity debt caused by the decline in <i>M pneumoniae</i> during the COVID-19 pandemic. While the severity of <i>M pneumoniae</i> infections did not change in 2023-2024, the five-fold increase in <i>M pneumoniae</i>-induced rash and mucositis in children and adolescents highlights <i>M pneumoniae</i> as an important pathogen causing mucocutaneous eruptions.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Innovation Fund Denmark and Rigshospitalets Forskningsfond.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dungu</LastName><ForeName>Kia H S</ForeName><Initials>KHS</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Mette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartling</LastName><ForeName>Ulla</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Hans Christian Andersen Children's Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lise H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Allan Bybeck</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Lisbeth S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Herlev University Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toustrup</LastName><ForeName>Lise B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Lotte H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Hospital of Southern Denmark, Aabenraa, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Kathrin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Hillerød University Hospital, Hillerød, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthesen</LastName><ForeName>Kirstine T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordholm</LastName><ForeName>Anne C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uldum</LastName><ForeName>Søren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emborg</LastName><ForeName>Hanne-Dorthe</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rytter</LastName><ForeName>Maren J H</ForeName><Initials>MJH</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Slagelse Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Ulrikka</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">MIRM</Keyword><Keyword MajorTopicYN="N">Mycoplasma</Keyword><Keyword MajorTopicYN="N">Mycoplasma induced rash and mucositis</Keyword><Keyword MajorTopicYN="N">Mycoplasma pneumoniae</Keyword><Keyword MajorTopicYN="N">Mycositis</Keyword><Keyword MajorTopicYN="N">RIME</Keyword><Keyword MajorTopicYN="N">Reactive infectious mucocutaneous eruptions</Keyword><Keyword MajorTopicYN="N">Resurgence</Keyword></KeywordList><CoiStatement>We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39469091</ArticleId><ArticleId IdType="pmc">PMC11513821</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2024.101103</ArticleId><ArticleId IdType="pii">S2666-7762(24)00270-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meyer Sauteur P.M., Beeton M.L., European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) Study Group Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe. 2024;5:e100–e101.</Citation><ArticleIdList><ArticleId IdType="pubmed">38008103</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO statement on reported clusters of respiratory illness in children in northern China. https://www.who.int/news/item/22-11-2023-who-statement-on-reported-clusters-of-respiratory-illness-in-children-in-northern-china</Citation></Reference><Reference><Citation>Communicable disease threats report, 26 November - 2 December 2023, week 48. 2023. https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-26-november-2-december-2023-week-48</Citation></Reference><Reference><Citation>Meyer Sauteur P.M., Chalker V.J., Berger C., Nir-Paz R., Beeton M.L., ESGMAC and the ESGMAC–MyCOVID Study Group Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Lancet Microbe. 2022;3:e897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371584</ArticleId><ArticleId IdType="pubmed">35964636</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell R., Saravanos G., Britton P.N. Unintended impacts of COVID-19 on the epidemiology and burden of paediatric respiratory infections. Paediatr Respir Rev. 2023 doi: 10.1016/j.prrv.2023.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2023.07.004</ArticleId><ArticleId IdType="pubmed">37580220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U., Nielsen J., Nielsen J.S.A., et al. The magnitude and severity of paediatric RSV infections in 2022-2023: a Danish nationwide cohort study. Acta Paediatr. 2023;112:2199–2201.</Citation><ArticleIdList><ArticleId IdType="pubmed">37329312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U., Hartling U.B., Munkstrup C., et al. Invasive group A streptococcal infections in children and adolescents in Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, population-based cohort study. Lancet Child Adolesc Health. 2024;8:112–121.</Citation><ArticleIdList><ArticleId IdType="pubmed">38103567</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdstock V., Twynam-Perkins J., Bradnock T., et al. National case series of group A streptococcus pleural empyema in children: clinical and microbiological features. Lancet Infect Dis. 2023;23:154–156.</Citation><ArticleIdList><ArticleId IdType="pubmed">36634683</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kempen E.B., Bruijning-Verhagen P.C.J., Borensztajn D., et al. Increase in invasive group a streptococcal infections in children in The Netherlands, A survey among 7 hospitals in 2022. Pediatr Infect Dis J. 2023;42:e122–e124.</Citation><ArticleIdList><ArticleId IdType="pubmed">36728741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolluyt D.C., Euser S.M., Souverein D., et al. Increased incidence of Mycoplasma pneumoniae infections and hospital admissions in The Netherlands, November to December 2023. Euro Surveill. 2024;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10986650</ArticleId><ArticleId IdType="pubmed">38275014</ArticleId></ArticleIdList></Reference><Reference><Citation>Edouard S., Boughammoura H., Colson P., La Scola B., Fournier P.E., Fenollar F. Early release - large-scale outbreak of mycoplasma pneumoniae infection, Marseille, France, 2023–2024. Emerg Infect Dis. 2024;30(7):1481–1484. doi: 10.3201/eid3007.240315.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid3007.240315</ArticleId><ArticleId IdType="pmc">PMC11210650</ArticleId><ArticleId IdType="pubmed">38816344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordholm A.C., Søborg B., Jokelainen P., et al. Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill. 2024;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10785206</ArticleId><ArticleId IdType="pubmed">38214084</ArticleId></ArticleIdList></Reference><Reference><Citation>Edens C., Clopper B.R., DeVies J., et al. Notes from the field: reemergence of mycoplasma pneumoniae infections in children and adolescents after the COVID-19 pandemic, United States, 2018–2024. MMWR Morb Mortal Wkly Rep. 2024;73:149–151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10899077</ArticleId><ArticleId IdType="pubmed">38386615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.-B., He W., Gui Y.H., et al. Current Mycoplasma pneumoniae epidemic among children in Shanghai: unusual pneumonia caused by usual pathogen. World J Pediatr. 2024;20:5–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">38231466</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  . 2024. About Mycoplasma pneumoniae Infection. Mycoplasma pneumoniae infection.https://www.cdc.gov/mycoplasma/about/index.html</Citation></Reference><Reference><Citation>Waites K.B., Xiao L., Liu Y., Balish M.F., Atkinson T.P. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30:747–809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5475226</ArticleId><ArticleId IdType="pubmed">28539503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon O., Oster Y., Michael-Gayego A., et al. The clinical presentation of pediatric mycoplasma pneumoniae infections-A single center cohort. Pediatr Infect Dis J. 2019;38:698–705.</Citation><ArticleIdList><ArticleId IdType="pubmed">30985519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Zhang B. Mycoplasma-induced rash and mucositis. N Engl J Med. 2023;389:1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">37888919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramien M.L., Bruckner A.L. Mucocutaneous eruptions in acutely ill pediatric patients-think of mycoplasma pneumoniae (and other infections) first. JAMA Dermatol. 2020;156:124–125.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramien M.L., Bahubeshi A., Lara-Corrales I., et al. Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria. Br J Dermatol. 2021;185:447–449.</Citation><ArticleIdList><ArticleId IdType="pubmed">33730370</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C.X., Hussain S.H. Recurrent reactive infectious mucocutaneous eruption: a retrospective cohort study. J Am Acad Dermatol. 2023;89:361–364.</Citation><ArticleIdList><ArticleId IdType="pubmed">36997070</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Sauteur P.M., Theiler M., Buettcher M., Seiler M., Weibel L., Berger C. Frequency and clinical presentation of mucocutaneous disease due to mycoplasma pneumoniae infection in children with community-acquired pneumonia. JAMA Dermatol. 2020;156:144–150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990853</ArticleId><ArticleId IdType="pubmed">31851288</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan T.N., Mathes E.F., Frieden I., Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239–245.</Citation><ArticleIdList><ArticleId IdType="pubmed">25592340</ArticleId></ArticleIdList></Reference><Reference><Citation>Voldstedlund M., Haarh M., Mølbak K., the MiBa Board of Representatives MiBa board of representatives. The Danish microbiology Database (MiBa) 2010 to 2013. Euro Surveill. 2014;19</Citation><ArticleIdList><ArticleId IdType="pubmed">24434175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen J.N., Voldstedlund M., Andersen R.L., et al. Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 2010;15</Citation><ArticleIdList><ArticleId IdType="pubmed">21087593</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Sauteur P.M., Beeton M.L., Uldum S.A., et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9101966</ArticleId><ArticleId IdType="pubmed">35551702</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumke R., Benitez A.J., Chalker V., et al. Multi-center evaluation of one commercial and 12 in-house real-time PCR assays for detection of Mycoplasma pneumoniae. Diagn Microbiol Infect Dis. 2017;88:111–114.</Citation><ArticleIdList><ArticleId IdType="pubmed">28318608</ArticleId></ArticleIdList></Reference><Reference><Citation>BioGX . 2024. Mycoplasma pneumoniae, Legionella pneumophila, Chlamydia pneumoniae, Pneumocystis jirovecii open system reagents for BD MAXTM.</Citation></Reference><Reference><Citation>BIOFIRE respiratory 2.1 (RP 2.1) Panel. bioMérieux website. https://www.biomerieux.com/us/en/our-offer/clinical-products/biofire-respiratory-panels.html</Citation></Reference><Reference><Citation>QIAstat-Dx US. https://www.qiagen.com/us/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-na</Citation></Reference><Reference><Citation>Lynge E., Sandegaard J.L., Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39:30–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775347</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M., Schmidt S.A.J., Sandegaard J.L., Ehrenstein V., Pedersen L., Sørensen H.T. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson T.P., Waites K.B. Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J. 2014;33:92–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">24346598</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy S.A., MacGregor D., Mahant S., Richardson S.E., Bitnun A. Neurological complications of PCR-proven M. Pneumoniae infections in children: prodromal illness duration may reflect pathogenetic mechanism. Clin Infect Dis. 2015;61:1092–1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">26084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Li S., Yang H., Chen Z., Zhou Z. Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China. Lancet Microbe. 2024;5:e515.</Citation><ArticleIdList><ArticleId IdType="pubmed">38244553</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R., Levy C., Rybak A., Angoulvant F., Ouldali N., Grimprel E. Immune debt: recrudescence of disease and confirmation of a contested concept. Infect Dis Now. 2023;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9756601</ArticleId><ArticleId IdType="pubmed">36535583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pánisová E., Unger W.W.J., Berger C., Meyer Sauteur P.M. Mycoplasma pneumoniae-specific IFN-γ-Producing CD4+ effector-memory T cells correlate with pulmonary disease. Am J Respir Cell Mol Biol. 2021;64:143–146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7780996</ArticleId><ArticleId IdType="pubmed">33385212</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M. Classification of extrapulmonary manifestations due to mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729911</ArticleId><ArticleId IdType="pubmed">26858701</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulou V.E., Lempesis I.G., Sklapani P., Trakas N., Spandidos D.A. Exploring the pathogenetic mechanisms of mycoplasmapneumoniae (review) Exp Ther Med. 2024;28:271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11097136</ArticleId><ArticleId IdType="pubmed">38765654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Luo Y., Li L., et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia. Front Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10250694</ArticleId><ArticleId IdType="pubmed">37304280</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Liu F., Lu M.-P., Zheng Q., Chen Z.-M. Increased T cell activation in BALF from children with Mycoplasma pneumoniae pneumonia. Pediatr Pulmonol. 2015;50:814–819.</Citation><ArticleIdList><ArticleId IdType="pubmed">25157471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan R., van der Beek B.A., Ben-Shimol S., et al. The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study. EBioMedicine. 2023;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970381</ArticleId><ArticleId IdType="pubmed">36857965</ArticleId></ArticleIdList></Reference><Reference><Citation>Spuesens E.B.M., Fraaij P.L.A., Visser E.G., et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653782</ArticleId><ArticleId IdType="pubmed">23690754</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenen M.H., de Groot R.C.A., de Steenhuijsen Piters W.A.A., et al. Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota. EBioMedicine. 2023;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10679896</ArticleId><ArticleId IdType="pubmed">37950996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Xie G., Liu Y., et al. Different nasopharynx and oropharynx microbiota imbalance in children with Mycoplasma pneumoniae or influenza virus infection. Microb Pathog. 2020;144</Citation><ArticleIdList><ArticleId IdType="pubmed">32278696</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Ma J., Li M., et al. Species-level respiratory microbiome profiling for etiologic diagnosis of children pneumonia using full length 16S rRNA gene sequencing. Indian J Med Microbiol. 2023;43:11–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">36241528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Xi Z., Shi Y., et al. Highly homogeneous microbial communities dominated by Mycoplasma pneumoniae instead of increased resistance to macrolide antibiotics is the characteristic of lower respiratory tract microbiome of children with refractory Mycoplasma pneumoniae pneumonia. Transl Pediatr. 2021;10:604–615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8039789</ArticleId><ArticleId IdType="pubmed">33850819</ArticleId></ArticleIdList></Reference><Reference><Citation>Méndez-Echevarría A., Calle-Miguel L., Miralbés S., et al. Increased severity of mycoplasma pneumoniae infections in Spanish children. Pediatr Infect Dis J. 2024 doi: 10.1097/INF.0000000000004461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000004461</ArticleId><ArticleId IdType="pubmed">38920379</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Sauteur P.M., Theiler M., Bogatu B. Mycoplasma pneumoniae-associated angioedema. JAAD Case Rep. 2021;9:52–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893324</ArticleId><ArticleId IdType="pubmed">33644281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U., Holm M., Hartling U.B., et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health. 2022;6:459–465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9072929</ArticleId><ArticleId IdType="pubmed">35526537</ArticleId></ArticleIdList></Reference><Reference><Citation>Finland M., Jolliffe L.S., Parker F. Pneumonia and erythema multiforme exudativum; report of four cases and three autopsies. Am J Med. 1948;4:473–492.</Citation><ArticleIdList><ArticleId IdType="pubmed">18909450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Li X., Tang J., et al. Mycoplasma infection aggravates cardiac involvements in Kawasaki diseases: a retrospective study. Front Immunol. 2024;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10832023</ArticleId><ArticleId IdType="pubmed">38304251</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>